Table 1.

Immunogenicity and protective efficacy against malaria sporozoite challenge from representative studies carried out in our laboratory

	Vaccination regime
	Mouse					Human
	DF	DM	FM	MF	AM1	D(D)DM	FFM
IFN-γ spot-forming cells/106 spleen cells (mouse) or PBMC (human)	750	1200	3200	3100	1500	1200 CD4	400–500 CD4/CD8
Percentage of individuals protected from challenge with sporozoites	12·5	17·5	67·5	37·5	100
Percentage reduction in infected liver cells						80	92

Mouse results (refs ^{52, 53})and human data (refs ^54–56) have been previously described in detail.

¹Separate study.

A, adenovirus priming; D, DNA priming; F, FP9 priming; IFN-γ, interferon-γ; M, modified vaccinia Ankara (MVA) boosting; PBMC, peripheral blood mononuclear cells.

Priming was multiple in the human studies.